Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;52(6):1893-7.
doi: 10.1128/JCM.03484-13. Epub 2014 Mar 19.

Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany

Affiliations

Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany

Martin Kaase et al. J Clin Microbiol. 2014 Jun.

Erratum in

  • J Clin Microbiol. 2014 Aug;52(8):3135

Abstract

Due to the increase in multidrug-resistant Enterobacteriaceae, the interest in older antimicrobial agents, like fosfomycin, has increased. In this study, we used agar dilution for testing susceptibilities to fosfomycin in a collection of 107 carbapenem-nonsusceptible Enterobacteriaceae isolates, of which 80 produced various types of carbapenemases, including KPC, VIM, NDM, and OXA-48. Overall, 78% of the strains had fosfomycin MICs of ≤ 32 mg/liter and were thus considered to be susceptible according to the current EUCAST breakpoint. The MIC50 and MIC90 were 8 mg/liter and 512 mg/liter, respectively. Escherichia coli strains had significantly lower fosfomycin MICs than the Klebsiella pneumoniae and Enterobacter cloacae strains. Furthermore, comparisons of the susceptibility testing methods, like Etest and disk diffusion, were performed against agar dilution as the reference method. Essential agreement between Etest and agar dilution was 78.9%, and categorical agreement between the two methods was 92.5%, with 20% very major errors and 2.6% major errors. Disk diffusion was studied with 50-μg and 200-μg fosfomycin disks, but no inhibition zone breakpoint that reduced very major and major errors to an acceptable level was found. Etest and disk diffusion showed poor agreement with fosfomycin agar dilution.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Bland-Altman analysis of agreement between Etest and agar dilution. The differences of the log2-transformed MICs obtained by agar dilution and Etest are plotted against their mean MIC values. The solid line represents the mean of the differences, the dotted lines indicate the lower and upper limits of the 95% confidence interval. The dashed line represents the linear fit between the mean MIC values and the difference between the log2-transformed MICs obtained with the two methods.
FIG 2
FIG 2
Scattergram of MICs versus zone diameters for the 200-μg fosfomycin disk. The horizontal dashed line represents the EUCAST breakpoint for fosfomycin. The vertical dash-dot line indicates the breakpoint proposed by Lu et al. (17), and the vertical dotted line indicates the breakpoint proposed by Pasteran et al. (18).
FIG 3
FIG 3
Scattergram of MIC versus zone diameters for 50-μg fosfomycin disk. The horizontal dashed line represents the EUCAST breakpoint for fosfomycin. The vertical dotted line indicates the breakpoint proposed by Pasteran et al. (18).

References

    1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25:682–707. 10.1128/CMR.05035-11 - DOI - PMC - PubMed
    1. Queenan AM, Bush K. 2007. Carbapenemases: the versatile beta-lactamases. Clin. Microbiol. Rev. 20:440–458, table of contents. 10.1128/CMR.00001-07 - DOI - PMC - PubMed
    1. Keating GM. 2013. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 73:1951–1966. 10.1007/s40265-013-0143-y - DOI - PubMed
    1. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. 2013. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int. J. Antimicrob. Agents 43:52–59. 10.1016/j.ijantimicag.2013.09.010 - DOI - PubMed
    1. Michalopoulos AS, Livaditis IG, Gougoutas V. 2011. The revival of fosfomycin. Int. J. Infect. Dis. 15:e732–e739. 10.1016/j.ijid.2011.07.007 - DOI - PubMed

Publication types

MeSH terms